Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of olesoxime in non-ambulant spinal muscular atrophy type 2 or 3 patients aged 3–25 years
2010-020386-24Phase 2
- Sponsor
- Trophos
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal muscular atrophy type 2 (SMA2) and Spinal muscular atrophy type 3 (SMA3) comparing Olesoxime arm with Placebo arm (2 arms). Primary endpoint: Motor Function Measure (MFM) D1+D2 score.
02
Drugs
olesoxime
03
Conditions
spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on 2010-020386-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020386-24.